Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

GALT has been the topic of several other reports. BidaskClub raised Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 15th. HC Wainwright lifted their price objective on Galectin Therapeutics Inc. Common Stock to $12.00 and gave the company a “buy” rating in a research note on Tuesday, May 15th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Galectin Therapeutics Inc. Common Stock has a consensus rating of “Buy” and an average price target of $6.94.

NASDAQ GALT opened at $4.04 on Tuesday. The stock has a market capitalization of $182.83 million, a PE ratio of -8.24 and a beta of 2.29. Galectin Therapeutics Inc. Common Stock has a 1-year low of $1.28 and a 1-year high of $9.49.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last released its quarterly earnings data on Friday, May 11th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. sell-side analysts anticipate that Galectin Therapeutics Inc. Common Stock will post -0.46 earnings per share for the current fiscal year.

In related news, COO Harold H. Shlevin sold 119,200 shares of the firm’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $5.06, for a total transaction of $603,152.00. Following the sale, the chief operating officer now directly owns 103,914 shares in the company, valued at approximately $525,804.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Jack W. Callicutt sold 46,651 shares of the firm’s stock in a transaction dated Thursday, May 31st. The shares were sold at an average price of $5.00, for a total value of $233,255.00. Following the sale, the chief financial officer now owns 47,911 shares in the company, valued at $239,555. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,743,263 shares of company stock worth $11,905,122. Company insiders own 45.20% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Tibra Equities Europe Ltd purchased a new stake in shares of Galectin Therapeutics Inc. Common Stock during the 1st quarter valued at about $301,000. A.R.T. Advisors LLC raised its holdings in shares of Galectin Therapeutics Inc. Common Stock by 60.2% during the 1st quarter. A.R.T. Advisors LLC now owns 57,775 shares of the company’s stock valued at $273,000 after buying an additional 21,704 shares during the period. LPL Financial LLC purchased a new stake in shares of Galectin Therapeutics Inc. Common Stock during the 1st quarter valued at about $112,000. Benchmark Capital Advisors raised its holdings in shares of Galectin Therapeutics Inc. Common Stock by 19.7% during the 1st quarter. Benchmark Capital Advisors now owns 221,700 shares of the company’s stock valued at $1,051,000 after buying an additional 36,500 shares during the period. Finally, D.A. Davidson & CO. raised its holdings in shares of Galectin Therapeutics Inc. Common Stock by 6.3% during the 1st quarter. D.A. Davidson & CO. now owns 731,300 shares of the company’s stock valued at $3,466,000 after buying an additional 43,147 shares during the period. Institutional investors and hedge funds own 11.87% of the company’s stock.

About Galectin Therapeutics Inc. Common Stock

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Featured Article: How to Use the New Google Finance Tool

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.